Article Versions Notes

Chi C, Harth L, Galera MR, Torrealba MP, Vadivel CK, Geisler C, Bonefeld CM, Nielsen PR, Bzorek M, Becker JC, et al. Concomitant Inhibition of FASN and SREBP Provides a Promising Therapy for CTCL. Cancers. 2022; 14(18):4491. https://doi.org/10.3390/cancers14184491

Chi, Cheng, Lisa Harth, Marina Ramírez Galera, Marina Passos Torrealba, Chella Krishna Vadivel, Carsten Geisler, Charlotte Menné Bonefeld, Pia Rude Nielsen, Michael Bzorek, Jürgen C. Becker, and et al. 2022. "Concomitant Inhibition of FASN and SREBP Provides a Promising Therapy for CTCL" Cancers 14, no. 18: 4491. https://doi.org/10.3390/cancers14184491

Chi, C., Harth, L., Galera, M. R., Torrealba, M. P., Vadivel, C. K., Geisler, C., Bonefeld, C. M., Nielsen, P. R., Bzorek, M., Becker, J. C., Gjerdrum, L. M. R., Ødum, N., & Woetmann, A. (2022). Concomitant Inhibition of FASN and SREBP Provides a Promising Therapy for CTCL. Cancers, 14(18), 4491. https://doi.org/10.3390/cancers14184491